Global Wellness’ Shanti Therapeutics Fast Tracking Their First-In-Man MDMA Trials for Pain

Human brain
Focus on Chronic Pain Market with Psychedelics

 Vancouver, British Columbia, September 7th 2021 Global Wellness Strategies Inc. (formerly Redfund Capital Corp.)(CSE: LOAN) (Frankfurt:O3X4) (OTCQB: PNNRF) (“Global” or the “Company”) updates Shanti Therapeutics’ developments; fast tracking First-In-Man (FIM) human trials in Australia for MDMA. 

Global Wellness recently announced the signing of a definitive agreement to acquire 100% of Shanti Therapeutics (read the release here). Shanti is focused on psychedelic MDMA-based drug development and becoming one of the first companies solving the puzzle of chronic pain with MDMA-based medicines utilizing clinical trials for the purposes of novel drug development. 

Shanti Therapeutics Update: 

The team at Shanti in Melbourne is finalizing their clinical protocol with a view to submit for ethics approval in the next few weeks. Nonetheless; preparation has begun for an Australian FIH (First-in-Human) proof of concept trial This trial will help identify the magnitude of the effect size of MDMA in treating pain which will guide the sample size determination for future pivotal clinical trials. 

MDMA has shown promise for PTSD, but the drug alone is unlikely to be a cure. The illegal substance, commonly known as Molly in the 1980’s was known as a college party drug for so long that many still do not believe MDMA paired with psychotherapy improves PTSD pathogenesis. Globally there are approx. 20 significantly funded companies (both listed and unlisted) conducting research and clinical trials into the potential applications (pain management, mental health, PTSD) of Ketamine, Psilocybin, DMT and MDMA and their respective derivatives / compounds. 

“Finding new drug solutions to the puzzle of chronic pain is novel and innovative. Shanti is an early mover with respect to entheogens (psychedelics) being used to modulate the psychosocial component of pain. Concurrent, with the trial being executed in Australia, a pre-IND application to the FDA will be conducted to help identify the best regulatory strategy to a new drug approval.” said Meris Kott CEO, Global Wellness Strategies. 

About Global Wellness Strategies 

Global Wellness Strategies is a prospect generator that provides high growth companies with financial, operational, and management assistance in the fast-growing market for wellness consumer products. The focus of the Company is on global wellness, psychedelics, mycology, hemp and CBD, healthcare-related target companies. 

For further information visit websites: and 

Or Contact Meris Kott CEO 604.484.0355 or email to 

Further information about the Company is available on under the Company’s profile. 

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain statements contained in this release may constitute “forward–looking statements” or “forward-looking information” (collectively “forward-looking information”) as those terms are used in the Private Securities Litigation Reform Act of 1995 and similar Canadian laws. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “anticipates” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the business of the Company, its financing and certain corporate changes. The forward-looking information contained in this release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein. 



February 10, 2022

GWS Signs MDMA Supply Agreement with PharmAla Biotech​

The Shanti Therapeutics Focus on Chronic Pain Market with Psychedelics